1. Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021; 79: 82-104.
2.
Raspollini MR, Comperat EM, Lopez-Beltran A, et al. News in the classification of WHO 2022 bladder tumors. Pathologica 2022; 115: 32-40.
3.
Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 244-258.
4.
Giudici N, Bonne F, Blarer J, Minoli M, Krentel F, Seiler R. Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. Transl Androl Urol 2021; 10: 4036-4050.
5.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.
6.
Jubber I, Ong S, Bukavina L, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol 2023; 84: 176-190.
7.
Ripoll J, Ramos M, Montano J, Pons J, Ameijide A, Franch P. Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival. BMC Cancer 2021; 21: 676.
8.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-745.
9.
Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-241.
10.
Gontero P, Birtle A, Capoun O, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – a summary of the 2024 Guidelines Update. Eur Urol 2024; S0302-2838: 02514-4.
11.
Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011; 30: 127-138.
12.
Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells 2019; 8: 497.
13.
Herrmann H, Strelkov SV, Burkhard P, Aebi U. Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 2009; 119: 1772-1783.
14.
Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008; 129: 705-733.
15.
Doganyigit Z, Eroglu E, Okan A. Intermediate filament proteins are reliable immunohistological biomarkers to help diagnose multiple tissue-specific diseases. Anat Histol Embryol 2023; 52: 655-672.
16.
Menz A, Weitbrecht T, Gorbokon N, et al. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Mol Med 2021; 27: 16.
17.
Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000; 13: 962-972.
18.
Ingenwerth M, Nyirady P, Hadaschik B, Szarvas T, Reis H. The prognostic value of cytokeratin and extracellular collagen expression in urinary bladder cancer. Curr Mol Med 2022; 22: 941-949.
19.
Skowron MA, Niegisch G, Fritz G, et al. Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. J Exp Clin Cancer Res 2015; 34: 144.
20.
Spilka R, Ernst C, Bergler H, et al. eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordrecht) 2014; 37: 253-267.
21.
Runge J, Garbers C, Lokau J. The role of interleukin-6 classic and trans-signaling and interleukin-11 classic signaling in gastric cancer cells. Contemp Oncol 2024; 28: 105-113.
22.
Kespohl B, Hegele AL, Düsterhöft S, et al. Molecular characterization of the craniosynostosis-associated interleukin-11 receptor variants p.T306_S308dup and p.E364_V368del. FEBS J 2024; 291: 1667-1683.
23.
Ahmad I, Lokau J, Kespohl B, et al. The interleukin-11 receptor variant p.W307R results in craniosynostosis in humans. Sci Rep 2023; 13: 13479.
24.
Cattan N, Rochet N, Mazeau C, et al. Establishment of two new human bladder carcinoma cell lines, CAL 29 and CAL 185. Comparative study of cell scattering and epithelial to mesenchyme transition induced by growth factors. Br J Cancer 2001; 85: 1412-1417.
25.
O’Toole C, Price ZH, Ohnuki Y, Unsgaard B. Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. Br J Cancer 1978; 38: 64-76.
26.
Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973; 11: 765-773.
27.
Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D. Systematic review: characteristics and preclinical uses of bladder cancer cell lines. Bladder Cancer 2018; 4: 169-183.
28.
Asamoto M, Fukushima S, Tatemoto Y, Yamada K, Fukui S, Mori M. Immunohistochemical expression of keratin proteins in urinary bladder carcinoma. Pathol Res Pract 1989; 184: 194-201.
29.
Chivu-Economescu M, Dragu DL, Necula LG, et al. Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells. Gastric Cancer 2017; 20: 948-959.
30.
Li C, Su H, Ruan C, Li X. Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells, as well as the activation of AKT and ERK pathway. Folia Histochem Cytobiol 2021; 59: 40-48.
31.
Yin L, Li Q, Mrdenovic S, et al. KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway. Breast Cancer Res 2022; 24: 7.
